Colomba A, et al. (2008) Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas. Oncogene 27, 2728-36 17998938

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

Y343-p - NPM-ALK (human) ▲

Modsite: DIyRAsyyRKGGCAM GenPept Orthologous residues NPM‑ALK (human): Y343‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  lymphoma, anaplastic large cell lymphoma, T cell lymphoma Relevant cell lines - cell types - tissues:  3T3 (fibroblast), BaF3 ('B lymphocyte, precursor'), Karpas-299 (T lymphocyte), lymphocyte-blood Cellular systems studied:  cell lines, primary cells Species studied:  human, mouse Comments:  Cost cells Downstream Regulation Effect of modification (function):  molecular association, regulation Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays VAV3 (human) SH2 Induces co-immunoprecipitation

Y664-p - NPM-ALK (human) ▲

Modsite: TAPGAGHyEDTILKS GenPept Orthologous residues NPM‑ALK (human): Y664‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  lymphoma, anaplastic large cell lymphoma, T cell lymphoma Relevant cell lines - cell types - tissues:  3T3 (fibroblast), BaF3 ('B lymphocyte, precursor'), Karpas-299 (T lymphocyte), lymphocyte-blood Cellular systems studied:  cell lines, primary cells Species studied:  human, mouse Comments:  Cost cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes WHI-P154 decrease LY294002 no change compared to control SU6656 decrease

Y173-p - VAV3 (human) ▲

Modsite: EDEGGEVyEDLMKAE SwissProt Entrez-Gene Orthologous residues VAV3 (human): Y173‑p, VAV3 iso4 (human): Y173‑p, VAV3 (mouse): Y173‑p, VAV3 (rat): Y173‑p Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE Src (human) pharmacological inhibitor of upstream enzyme, phospho-antibody, siRNA inhibition of enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes WHI-P154 decrease SU6656 decrease

S199-p - PAK1 (mouse) ▲

Modsite: PRPEHTKsVYTRsVI SwissProt Entrez-Gene Orthologous residues PAK1 (human): S199‑p, PAK1 (mouse): S199‑p, PAK1 (rat): S198‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  lymphoma, anaplastic large cell lymphoma, T cell lymphoma Relevant cell lines - cell types - tissues:  3T3 (fibroblast), BaF3 ('B lymphocyte, precursor'), Karpas-299 (T lymphocyte), lymphocyte-blood Cellular systems studied:  cell lines, primary cells Species studied:  human, mouse Comments:  Cost cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes NPM-ALK (human) increase LY294002 NPM-ALK (human) inhibit treatment-induced increase SU6656 NPM-ALK (human) inhibit treatment-induced increase

S204-p - PAK1 (mouse) ▲

Modsite: TKsVYTRsVIEPLPV SwissProt Entrez-Gene Orthologous residues PAK1 (human): S204‑p, PAK1 (mouse): S204‑p, PAK1 (rat): S203‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  lymphoma, anaplastic large cell lymphoma, T cell lymphoma Relevant cell lines - cell types - tissues:  3T3 (fibroblast), BaF3 ('B lymphocyte, precursor'), Karpas-299 (T lymphocyte), lymphocyte-blood Cellular systems studied:  cell lines, primary cells Species studied:  human, mouse Comments:  Cost cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes NPM-ALK (human) increase LY294002 NPM-ALK (human) inhibit treatment-induced increase SU6656 NPM-ALK (human) inhibit treatment-induced increase

S192-p - PAK2 (mouse) ▲

Modsite: PRPDHTKsIYtRsVI SwissProt Entrez-Gene Orthologous residues PAK2 (human): S192‑p, PAK2 (mouse): S192‑p, PAK2 (rat): S192‑p, PAK2 (rabbit): S192‑p, PAK2 (cow): S192‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  lymphoma, anaplastic large cell lymphoma, T cell lymphoma Relevant cell lines - cell types - tissues:  3T3 (fibroblast), BaF3 ('B lymphocyte, precursor'), Karpas-299 (T lymphocyte), lymphocyte-blood Cellular systems studied:  cell lines, primary cells Species studied:  human, mouse Comments:  Cost cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes NPM-ALK (human) increase LY294002 NPM-ALK (human) inhibit treatment-induced increase SU6656 NPM-ALK (human) inhibit treatment-induced increase

S197-p - PAK2 (mouse) ▲

Modsite: TKsIYtRsVIDPIPA SwissProt Entrez-Gene Orthologous residues PAK2 (human): S197‑p, PAK2 (mouse): S197‑p, PAK2 (rat): S197‑p, PAK2 (rabbit): S197‑p, PAK2 (cow): S197‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  lymphoma, anaplastic large cell lymphoma, T cell lymphoma Relevant cell lines - cell types - tissues:  3T3 (fibroblast), BaF3 ('B lymphocyte, precursor'), Karpas-299 (T lymphocyte), lymphocyte-blood Cellular systems studied:  cell lines, primary cells Species studied:  human, mouse Comments:  Cost cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes NPM-ALK (human) increase LY294002 NPM-ALK (human) inhibit treatment-induced increase SU6656 NPM-ALK (human) inhibit treatment-induced increase

Y173-p - VAV3 (mouse) ▲
Modsite: EDEGGEVyEDLMKAE SwissProt Entrez-Gene Orthologous residues VAV3 (human): Y173‑p, VAV3 iso4 (human): Y173‑p, VAV3 (mouse): Y173‑p, VAV3 (rat): Y173‑p Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes NPM-ALK (human) increase